Article
Emergency Medicine
Jonathan A. Summerlin, Nicholas Scaturo, Jeremy A. Lund, Kellie M. Wang, Marshall A. Frank
Summary: This study aimed to assess the adverse events associated with the rapid administration of undiluted IV levetiracetam. The study found that the rapid administration of undiluted IV levetiracetam in emergency department patients was associated with few adverse events.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2023)
Article
Veterinary Sciences
Patrick Roynard, Ann Bilderback, Curtis Wells Dewey
Summary: Ketamine 5 mg/kg IV bolus may be successful in treating RSE in dogs, but its efficacy in handling CS is limited. The incidence of adverse effects is low, but timing of administration should be carefully considered.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Article
Emergency Medicine
Zlatan Coralic, Jaideep Kapur, Kent R. Olson, James M. Chamberlain, Daniel Overbeek, Robert Silbergleit
Summary: This study describes the safety and efficacy of second-line antiseizure medications in a subset of patients with toxin-related precipitants of seizures/status epilepticus. The results showed that approximately 10% of adult patients with status epilepticus had toxin-related seizures, with alcohol withdrawal and cocaine/opioid use being the most common precipitants. Treatment with second-line agents successfully controlled seizures in 42% of the patients.
ANNALS OF EMERGENCY MEDICINE
(2022)
Article
Clinical Neurology
Mehmet Tolga Kole, Safiye Gunes Sager, Hatice Zeynel, Yakup Cag, Yasemin Akin
Summary: This study aimed to compare the efficacy of levetiracetam and phenytoin in treating convulsive status epilepticus and acute repetitive seizures, and identify the factors that cause seizure recurrence. The results showed that intravenous administration of levetiracetam was as effective as intravenous administration of phenytoin in stopping seizures and preventing seizure recurrence. However, active seizures on admission to the emergency department and an age of <36 months were significantly associated with seizure recurrence.
CHILDS NERVOUS SYSTEM
(2022)
Article
Pharmacology & Pharmacy
Lily Price, Lisa Garrity, Sarah Stiehl
Summary: The study aimed to evaluate the safety and tolerability of undiluted levetiracetam in pediatric patients. The results showed that undiluted levetiracetam, when administered at high doses, did not increase the incidence of adverse effects compared to diluted levetiracetam.
Review
Medicine, General & Internal
Jason Dell'Aquila, Varun Soti
Summary: In recent years, levetiracetam has emerged as a safer and more effective alternative to phenytoin in treating status epilepticus, as demonstrated by several clinical studies comparing the two drugs.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Pharmacology & Pharmacy
Abhishek G. Sathe, Usha Mishra, Vijay Ivaturi, Richard C. Brundage, James C. Cloyd, Jordan J. Elm, James M. Chamberlain, Robert Silbergleit, Jaideep Kapur, Daniel H. Lowenstein, Shlomo Shinnar, Hannah R. Cock, Nathan B. Fountain, Lynn Babcock, Lisa D. Coles
Summary: This study investigated the drug concentrations of LEV and VPA in young children with status epilepticus, providing valuable information on plasma concentrations and protein binding. LEV concentrations ranged widely while VPA concentrations were after a 40 mg/kg dose. Challenges in patient enrollment and blood sampling were noted, highlighting the need for further studies with larger sample sizes to evaluate exposure-response relationships in this emergent condition.
JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Neurosciences
Opeyemi Samson Osuntokun, Umar Faruq Abdulwahab, Nafisat Omolola Akanji, Kabiru Isola Adedokun, Adedayo Damilare Adekomi, Gbola Olayiwola
Summary: The study evaluated the anticonvulsant and neuroprotective effects of CBZ, LEV, and CBZ + LEV adjunctive treatment in CSE rat model. The treatments delayed seizure onset and reduced mortality significantly, while hippocampal concentrations of certain markers decreased in all treatment groups. Reactive astrogliosis in the hippocampus was mitigated by the treatments.
NEUROSCIENCE LETTERS
(2021)
Article
Clinical Neurology
Jennifer D'Anto, Isabelle Beuchat, Andrea O. Rossetti, Jan Novy
Summary: This study aimed to explore the correlation between high doses of clonazepam (CLZ) used for the treatment of status epilepticus (SE) and clinical outcomes. The study found that high doses of CLZ were more frequently used in younger patients with lower body weight and were associated with a higher rate of intubation for airways protection. However, the varying CLZ dose did not affect the treatment outcome in SE.
Review
Critical Care Medicine
Jennifer Ann Klowak, Mark Hewitt, Vanessa Catenacci, Mark Duffett, Bram Rochwerg, Kevin Jones, Karen Choong
Summary: The study identified seven randomized controlled trials with low certainty evidence that levetiracetam is comparble with phenytoin or fosphenytoin in treating benzodiazepine-refractory pediatric status epilepticus. Levetiracetam may cause less respiratory depression, but adverse event outcomes were limited by low event numbers. It is important for clinicians and guideline developers to weigh safety profiles when choosing between these agents.
PEDIATRIC CRITICAL CARE MEDICINE
(2021)
Review
Multidisciplinary Sciences
Shixin Wang, Xin Wu, Tao Xue, Zhaoming Song, Xin Tan, Xiaoou Sun, Zhong Wang
Summary: This meta-analysis compared the efficacy and safety of levetiracetam (LEV) and valproate (VPA) for the treatment of established status epilepticus (ESE). The results showed no significant difference between LEV and VPA in terms of seizure termination and treatment outcomes, as well as ICU admission, adverse events, and mortality.
Article
Clinical Neurology
Lothar Burghaus, Marie Madlener, Felix Kohle, Emanuel F. Bruno, Volker Limmroth, Gereon R. Fink, Michael P. Malter
Summary: Status epilepticus (SE) is a neurological emergency characterized by prolonged seizure activity. Prehospital management of SE is crucial, and this study investigated the impact of different treatment strategies, specifically focusing on levetiracetam. The results showed that the use of levetiracetam in the prehospital setting did not have a significant additional effect on SE parameters.
JOURNAL OF CLINICAL NEUROLOGY
(2023)
Article
Clinical Neurology
John Tyler Haller, Sophia Bonnin, John Radosevich
Summary: Rapid intravenous push administration of undiluted LEV is safe and well tolerated up to doses of 4500 mg, providing a means for rapid drug administration in neurological emergencies.
Article
Medicine, General & Internal
R. L. Wu, A. H. Idris, N. M. Berkowitz, M. Happe, M. R. Gaudinski, C. Buettner, L. Strom, S. F. Awan, L. S. A. Holman, F. Mendoza, I. J. Gordon, Z. Hu, A. Campos Chagas, L. T. Wang, L. Da Silva Pereira, J. R. Francica, N. K. Kisalu, B. J. Flynn, W. Shi, W-P Kong, S. O'Connell, S. H. Plummer, Allison Beck, A. McDermott, S. R. Narpala, L. Serebryannyy, M. Castro, R. Silva, M. Imam, I Pittman, S. P. Hickman, A. J. McDougal, A. E. Lukoskie, J. R. Murphy, J. G. Gall, K. Carlton, P. Morgan, E. Seo, J. A. Stein, S. Vazquez, S. Telscher, E. Capparelli, E. E. Coates, J. R. Mascola, J. E. Ledgerwood, L. K. Dropulic, R. A. Seder
Summary: This study evaluated the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and demonstrated its protective efficacy against controlled human malaria infection. L9LS was found to provide protection without evident safety concerns.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Clinical Neurology
Niccolo Orlandi, Emanuele Bartolini, Daniela Audenino, Mario Coletti Moja, Lidia Urso, Giuseppe d'Orsi, Giada Pauletto, Annacarmen Nilo, Lucia Zinno, Roberto Cappellani, Leila Zummo, Antonello Giordano, Filippo Dainese, Peiman Nazerian, Francesca Pescini, Simone Beretta, Fedele Dono, Luigi del Gaudio, Monica Ferlisi, Daniela Marino, Marta Piccioli, Rosaria Renna, Eleonora Rosati, Adriana Rum, Gionata Strigaro, Giada Giovannini, Stefano Meletti, Salvatore M. Cavalli, Margherita Contento, Salvatore Cottone, Maria Teresa Di Claudio, Irene Florindo, Martina Guadagni, Lorenzo Kiferle, Delia Lazzaretti, Matilde Lazzari, Daniele Lo Coco, Silvia Pradella, Klaudio Rikani, Davide Rodorigo, Annarita Sabetta, Luigi Sicurella, Valentina Tontini, Giulia Turchi, Anna E. Vaudano, Tiziano Zanoni
Summary: The study evaluated the use of intravenous brivaracetam (BRV) in status epilepticus (SE), showing its effectiveness and safety in SE treatment. Early response to BRV within 6 hours of SE onset was associated with shorter time to seizure resolution.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
(2021)
